Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products in Israel

 Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products in Israel

Kamada Collaborates with Alvotech to Commercialize its Six Biosimilar Products in Israel

Shots:

  • Kamada will commercialize Alvotech’s biosimilar portfolio consisting of 6 products in Israel, upon its Israeli Ministry of Health (IMOH) approval while Alvotech will remain responsible for development, manufacturing and supply of all products
  • The collaboration leverages Kamada’s expertise and presence in the Israeli market and enables Kamada to benefit from the long-term growth potential of the emerging class of biosimilar drugs
  • Alvotech’s biosimilar portfolio includes candidates targeting autoimmunity, oncology and, inflammatory conditions. If approved by IMOH, Kamada will launch PF708 (biosimilar, teriparatide) referencing Eli Lilly’s Forteo in 2020 with the anticipated launch of the remaining five products in 2023-2025

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Bio news

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post